突出的干扰器和目标之间有一个共同的特征,在目标缺席时,将早期戒烟效应转化为延迟戒烟效应
Wenjie Peng1, Yujun He1, Xinyu Shi1
1School of Psychology, South China Normal University, Guangzhou, 510631, Guangdong, China.
Cognitive research: principles and implications
|September 24, 2025
概括
一个突出的分心器.
科学领域:
- 认知心理学 认知心理学
- 视觉搜索研究 视觉搜索研究
背景情况:
- 一篇开创性的论文确定了早期戒烟效应 (EQE),当目标缺失时,分散注意力的因素会促使早期放弃任务.
- 对EQE对现实世界目标检测的影响及其潜在机制仍然是人们感兴趣的领域.
研究的目的:
- 研究如何增加目标和突出的分心因子之间的相似性影响早期戒烟效应 (EQE).
- 区分注意力抑制和搜索力作为驱动EQE的机制.
主要方法:
- 实验1:使用与目标不同颜色,大小和方向的突出分心器复制了EQE.
- 实验2:通过共享定向特征来观察其对EQE的影响,增加了目标-干扰器相似性.
主要成果:
- 实验1成功复制了EQE:在没有目标的试验中,反应更快,在有目标的试验中,错误率更高.
- 在实验2中,随着目标与干扰器的相似性增加,EQE消失了;干扰器延迟了搜索时间,但没有影响错误率.
结论:
- 突出的干扰因子对目标检测的影响是由目标-干扰因子相似性调节的.
- 研究结果支持将注意力抑制作为EQE的关键子过程,而不是搜索力度的感觉.
更多相关视频
08:45A Dual Task Procedure Combined with Rapid Serial Visual Presentation to Test Attentional Blink for Nontargets
Published on: December 5, 2014
9.5K
05:58Using Rapid Serial Visual Presentation to Measure Set-Specific Capture, a Consequence of Distraction While Multitasking
Published on: August 29, 2018
9.2K
相关概念视频
Targets for Drug Action: Overview
9.2K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.2K
Drug-Receptor Interaction: Agonist
4.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.3K
Drug-Receptor Interaction: Antagonist
4.9K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
4.9K
Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.8K
Drugs Acting on Autonomic Ganglia: Stimulants
2.2K
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating...
2.2K
Adrenergic Agonists: Indirect-Acting Agents
2.8K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.8K
